Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

OBJECTIVES: To report results of subgroup analyses of bone mineral density (BMD) and bone turnover markers from a randomised, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor, in patients with rheumatoid arthritis (RA) concurrently receiving treatment...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Rheum Dis
Hlavní autoři: Dore, Robin K, Cohen, Stanley B, Lane, Nancy E, Palmer, William, Shergy, William, Zhou, Lifen, Wang, Huei, Tsuji, Wayne, Newmark, Richard
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6909937/
https://ncbi.nlm.nih.gov/pubmed/19734132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2009.112920
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky